ÑÇÖÞ×ÔοÊÓƵ

Laura A. Lambert
( out of 82 reviews )

Laura A. Lambert, MD, FACS

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Salt Lake City
801-587-4415

  • Dr. Laura Lambert is a Professor of Surgery and Director of the Peritoneal Malignancy Program at the ÑÇÖÞ×ÔοÊÓƵ of Utah. Dr. Lambert specializes in the care of patients requiring surgical treatment related to peritoneal carcinomatosis (cancer which has spread throughout the lining of the abdominal cavity) and gastrointestinal oncology. Dr. Lambert earned her undergraduate degree from Bowdoin College in Brunswick, Maine, and medical degree from Harvard Medical School in Boston Massachusetts. Her general surgery residency was done at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, which was followed by a two-year fellowship in surgical oncology at the ÑÇÖÞ×ÔοÊÓƵ of Texas MD Anderson Cancer Center in Houston, Texas. She obtained her board certification in hospice and palliative medicine in 2012 at the ÑÇÖÞ×ÔοÊÓƵ of Massachusetts in Worcester, Massachusetts. Dr. Lambert joined the faculty at the ÑÇÖÞ×ÔοÊÓƵ of Utah in 2018. Her main clinical focus is the surgical management of peritoneal carcinomatosis and the use of hyperthermic (heated) intraperitoneal chemotherapy (HIPEC). She has published and spoken extensively on HIPEC as well as the surgeon’s role in comprehensive palliative care.

    Specialties

    Board Certification

    American Board of Surgery

    Patient Rating

    5.0 /5
    ( out of 82 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 31, 2024
    HUNTSMAN CANCER CENTER

    Dr.Lambert throughly researched my case, finding scans from 2008 to help us come to a decision. We were very pleased with her plan for my case.

    October 10, 2024
    HUNTSMAN CANCER CENTER

    Dr. Lambert could not have treated me better. She was kind and caring and provided valuable information. My day was brighter after speaking with her. Thank you.

    September 14, 2024
    HUNTSMAN CANCER CENTER

    She is very knowledgeable & a caring physician

    September 12, 2024
    HUNTSMAN CANCER CENTER

    She is amazing! I appreciate the virtual call to start things off. She listened, explained, etc. I can't wait to meet her in person

    September 06, 2024
    HUNTSMAN CANCER CENTER

    Intelligent, great communicator, genuine, good listener, able to communicate difficult medical terms in layman's terms, respectful and kind.

    September 05, 2024
    HUNTSMAN CANCER CENTER

    Dr. Lambert is such a wonderful doctor! She is always very friendly and kind, and she always listens to my worries or concerns and gives me encouragement.

    July 31, 2024
    HUNTSMAN CANCER CENTER

    Having a five year doctor/patient relationship I feel as though above that were friends. She treats my wife who is my caregiver and a nurse the utmost respect for her knowledge and always asks for her thoughts and opinions. She gives answers to questions that are hard to tell someone and their loved ones again with respect, caring and understanding. A year ago I had a difficult time with complications following my HIPEC and was in the hospital for several weeks there were a few days my family were not able to be there. It was those days I got a hand squeezed and a pat as she told it's going to be okay, it's just going to take some time. She is a talented and intelligent doctor and an amazing surgeon. With that said'the simplest thing of her human touch was just as healing as any of her medical interventions. My wife Geri and my self love Dr Lambert. She is the most special of all specialists.

    July 18, 2024
    HUNTSMAN CANCER CENTER

    She is the BEST. I trust her completely.

    June 13, 2024
    HUNTSMAN CANCER CENTER

    She makes sure that you are heard.

    See More Patient Comments

  • Dr. Laura Lambert is a Professor of Surgery and Director of the Peritoneal Malignancy Program at the ÑÇÖÞ×ÔοÊÓƵ of Utah. Dr. Lambert specializes in the care of patients requiring surgical treatment related to peritoneal carcinomatosis (cancer which has spread throughout the lining of the abdominal cavity) and gastrointestinal oncology. Dr. Lambert earned her undergraduate degree from Bowdoin College in Brunswick, Maine, and medical degree from Harvard Medical School in Boston Massachusetts. Her general surgery residency was done at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, which was followed by a two-year fellowship in surgical oncology at the ÑÇÖÞ×ÔοÊÓƵ of Texas MD Anderson Cancer Center in Houston, Texas. She obtained her board certification in hospice and palliative medicine in 2012 at the ÑÇÖÞ×ÔοÊÓƵ of Massachusetts in Worcester, Massachusetts. Dr. Lambert joined the faculty at the ÑÇÖÞ×ÔοÊÓƵ of Utah in 2018. Her main clinical focus is the surgical management of peritoneal carcinomatosis and the use of hyperthermic (heated) intraperitoneal chemotherapy (HIPEC). She has published and spoken extensively on HIPEC as well as the surgeon’s role in comprehensive palliative care.

    Board Certification and Academic Information

    Academic Departments Surgery -Primary
    Academic Divisions Surgical Oncology
    Board Certification
    American Board of Surgery

    Education history

    Fellowship Surgical Oncology - ÑÇÖÞ×ÔοÊÓƵ of Texas MD Anderson Cancer Center Administrative Fellow
    Surgical Oncology - ÑÇÖÞ×ÔοÊÓƵ of Texas MD Anderson Cancer Center Fellow
    Chief Resident General Surgery - Dartmouth-Hitchcock Medical Center Chief Resident
    General Surgery - Dartmouth-Hitchcock Medical Center Resident
    Internship General Surgery - Dartmouth-Hitchcock Medical Center Intern
    Medicine - Harvard Medical School M.D.
    Undergraduate German & Economics - Bowdoin College B.A.

    Selected Publications

    Journal Article

    1. Kubi B, Nudotor R, Fackche N, Nizam W, Cloyd JM, Grotz TE, Fournier KF, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Patel SH, Lambert LA, Abbott DE, Vande Walle KA, Raoof M, Lee B, Maithel SK, Staley CA, Johnston FM, Greer JB (2021). Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Ann Surg Oncol, 28(8), 4499-4507. ()
    2. Bleicher J, Lambert LA (2021). A Palliative Approach to Management of Peritoneal Carcinomatosis and Malignant Ascites. Surg Oncol Clin N Am, 30(3), 475-490. ()
    3. Bleicher J, Lambert LA, Scaife CL, Colonna A (2021). Current management of malignant bowel obstructions: a survey of acute care surgeons and surgical oncologists. Trauma Surg Acute Care Open, 6(1), e000755. ()
    4. Bleicher J, Place A, Schoenhals S, Luppens CL, Grudziak J, Lambert LA, McCrum ML (2021). Drivers of Moral Distress in Surgical Intensive Care Providers: A Mixed Methods Study. J Surg Res, 266, 292-299. ()
    5. Fackche N, Schmocker RK, Kubi B, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Powers B, Dineen S, Veerapong J, Baumgartner JM, Clarke C, Gamblin TC, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Zaidi MY, Maithel SK, Johnston FM, Greer JB (2021). The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. J Gastrointest Surg. ()
    6. Lee RM, Gamboa AC, Turgeon MK, Zaidi MY, Kimbrough C, Leiting J, Grotz T, Lee AJ, Fournier K, Powers B, Dineen S, Baumgartner JM, Veerapong J, Mogal H, Clarke C, Wilson G, Patel S, Hendrix R, Lambert L, Pokrzywa C, Abbott DE, LaRocca CJ, Raoof M, Greer J, Johnston FM, Staley CA, Cloyd JM, Maithel SK, Russell MC (2020). A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. J Surg Oncol, 123(1), 187-195. ()
    7. Powers BD, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Maithel SK, Patel S, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Johnston FM, Greer J, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Imanirad I, Dessureault S, Dineen SP (2020). Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Ann Surg Oncol, 27(13), 4883-4891. ()
    8. Turgeon MK, Gamboa AC, Lee RM, Zaidi MY, Kimbrough C, Grotz T, Fournier K, Powers B, Dineen S, Veerapong J, Clarke C, Mogal H, Patel SH, Lambert L, Ronnekleiv-Kelly S, Raoof M, Fackche N, Greer JB, Staley CA, Cloyd JM, Maithel SK, Winer JH (2020). The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Ann Surg Oncol, 27(13), 4894-4907. ()
    9. Gamboa AC, Lee RM, Turgeon MK, Zaidi MY, Kimbrough CW, Grotz TE, Leiting J, Fournier K, Lee AJ, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Mogal H, Patel SH, Lee TC, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Cloyd JM, Maithel SK, Staley CA (2020). Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol, 27(13), 4980-4995. ()
    10. Hbner M, Kusamura S, Villeneuve L, Al-Niaimi A, Alyami M, Balonov K, Bell J, Bristow R, Guiral DC, Fagotti A, Falco LFR, Glehen O, Lambert L, Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar SP, Wadhwa A, Altman A, Fawcett W, Veerapong J, Nelson G (2020). Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations - Part II: Postoperative management and special considerations. Eur J Surg Oncol, 46(12), 2311-2323. ()
    11. Roife D, Powers BD, Zaidi MY, Staley CA, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lee B, Blakely A, Greer J, Johnston FM, Laskowitz D, Dessureault S, Dineen SP (2020). CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Ann Surg Oncol, 27(13), 4996-5004. ()
    12. Wiseman JT, Abdel-Misih S, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Eng O, Fackche N, Greer J, Pawlik TM, Cloyd JM (2020). A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surg Oncol, 37, 101492. ()
    13. Kubi B, Gunn J, Fackche N, Cloyd JM, Abdel-Misih S, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Patel SH, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Maithel SK, Staley CA, Johnston FM, Wang NY, Greer JB (2020). Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. J Surg Res, 255, 475-485. ()
    14. Eng OS, Blakely AM, Lafaro KJ, Fournier KF, Fackche NT, Johnston FM, Dineen S, Powers B, Hendrix R, Lambert LA, Ronnekleiv-Kelly S, Walle KV, Grotz TE, Leiting JL, Patel SH, Dhar VK, Baumgartner JM, Lowy AM, Clarke CN, Mogal H, Zaidi MY, Staley CA, Kimbrough C, Cloyd JM, Lee B, Raoof M (2020). Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. J Surg Oncol, 122(5), 980-985. ()
    15. Nevo ON, Lambert L (2020). Start the Right Way: A Foundation for Improving Connection to Service and People in Medical Education. Mil Med, 185(Suppl 3), 46-51. ()
    16. Leiting JL, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dessureault S, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Zaidi MY, Patel SH, Ahmad SA, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, LaRocca CJ, Johnston FM, Greer J, Grotz TE (2020). Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol, 12(7), 756-767. ()
    17. Beal EW, Suarez-Kelly LP, Kimbrough CW, Johnston FM, Greer J, Abbott DE, Pokrzywa C, Raoof M, Lee B, Grotz TE, Leiting JL, Fournier K, Lee AJ, Dineen SP, Powers B, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Russell MC, Zaidi MY, Patel SH, Dhar V, Lambert L, Hendrix RJ, Hays J, Abdel-Misih S, Cloyd JM (2020). Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. J Clin Med, 9(3). ()
    18. Beal EW, Ahmed A, Grotz T, Leiting J, Fournier KF, Lee AJ, Dineen S, Dessureault S, Baumgartner JM, Veerapong J, Clarke C, Strong E, Maithel SK, Zaidi MY, Patel S, Dhar V, Hendrix R, Lambert L, Johnston F, Fackche N, Raoof M, LaRocca C, Ronnekleiv-Kelly S, Pokrzywa C, Pawlik TM, Abdel-Misih S, Cloyd JM (2019). Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg, 219(3), 478-483. ()
    19. Wiseman JT, Kimbrough C, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Lee B, Fackche N, Greer J, Pawlik TM, Abdel-Misih S, Cloyd JM (2019). Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter? Ann Surg Oncol, 27(3), 783-792. ()
    20. Lee RM, Zaidi MY, Gamboa AC, Speegle S, Kimbrough CW, Cloyd JM, Leiting JL, Grotz TE, Lee AJ, Fournier KF, Powers BD, Dineen SP, Baumgartner J, Veerapong J, Clarke CN, Sussman JJ, Patel S, Hendrix RJ, Lambert LA, Vande Walle KA, Abbott DE, LaRocca CJ, Raoof M, Fackche N, Johnston FM, Staley CA, Maithel SK, Russell MC (2019). What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. Clin Colorectal Cancer, 19(1), e1-e7. ()
    21. Gamboa AC, Zaidi MY, Lee RM, Speegle S, Switchenko JM, Lipscomb J, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers BD, Lowy AM, Kotha NV, Clarke C, Gamblin TC, Patel SH, Lee TC, Lambert L, Hendrix RJ, Abbott DE, Vande Walle K, Lafaro K, Lee B, Johnston FM, Greer J, Russell MC, Staley CA, Maithel SK (2019). Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol, 27(1), 134-146. ()
    22. Hendrix RJ, Kassira JP, Lambert LA (2019). Elevated Maximum Core Body Temperature During Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) is Associated with Increased Postoperative Complications. Ann Surg Oncol, 27(1), 232-239. ()
    23. Levinsky NC, Morris MC, Wima K, Sussman JJ, Ahmad SA, Cloyd JM, Kimbrough C, Fournier K, Lee A, Dineen S, Dessureault S, Veerapong J, Baumgartner JM, Clarke C, Zaidi MY, Staley CA, Maithel SK, Leiting J, Grotz T, Lambert L, Hendrix RJ, Ronnekleiv-Kelly S, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Patel SH (2019). Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. J Gastrointest Surg, 24(1), 155-164. ()
    24. Zaidi MY, Lee RM, Gamboa AC, Speegle S, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Kelly KJ, Kotha NV, Clarke C, Gamblin TC, Patel SH, Lee TC, Hendrix RJ, Lambert L, Ronnekleiv-Kelly S, Pokrzywa C, Blakely AM, Lee B, Johnston FM, Fackche N, Russell MC, Maithel SK, Staley CA 3rd (2019). Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Ann Surg Oncol, 27(1), 156-164. ()
    25. Lee TC, Wima K, Sussman JJ, Ahmad SA, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Zaidi MY, Maithel SK, Leiting J, Grotz T, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Blakely AM, Lee B, Johnston FM, Greer J, Patel SH (2019). Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. J Gastrointest Surg, 24(1), 165-176. ()
    26. Leiting JL, Day CN, Harmsen WS, Cloyd JM, Abdel-Misih S, Fournier K, Lee AJ, Dineen S, Dessureault S, Veerapongh J, Baumgartner JM, Clarke C, Mogal H, Russell MC, Zaidi MY, Patel SH, Morris MC, Hendrix RJ, Lambert LA, Abbott DE, Pokrzywa C, Raoof M, Eng O, Johnston FM, Greer J, Grotz TE (2020). The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. Int J Hyperthermia, 37(1), 1182-1188. ()
    27. Hendrix RJ, Lambert LA (2019). ASO Author Reflections: Intraoperative Fluid Restriction During CRS-HIPEC-Less is More. Ann Surg Oncol, 26(Suppl 3), 575-576. ()
    28. Kotha NV, Baumgartner JM, Veerapong J, Cloyd JM, Ahmed A, Grotz TE, Leiting JL, Fournier K, Lee AJ, Dineen SP, Dessureault S, Clarke C, Mogal H, Zaidi MY, Russell MC, Patel SH, Sussman JJ, Dhar V, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Greer JB, Fackche N, Lowy AM, Kelly KJ (2019). Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Ann Surg Oncol, 26(7), 2234-2240. ()
    29. Lambert LA (2019). Invited Commentary. J Am Coll Surg, 228(6), 851. ()
    30. Zhu X, Salhab M, Tomaszewicz K, Meng X, Mathew C, Bathini V, Switzer B, Walter O, Cosar EF, Wang X, Lambert LA, Hutchinson LM (2018). Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms. Hum Pathol, 85, 260-269. ()
    31. Hendrix RJ, Damle A, Williams C, Harris A, Spanakis S, Lambert DH, Lambert LA (2018). Restrictive Intraoperative Fluid Therapy is Associated with Decreased Morbidity and Length of Stay Following Hyperthermic Intraperitoneal Chemoperfusion. Ann Surg Oncol, 26(2), 490-496. ()
    32. Lambert LA, Wiseman J (2018). Palliative Management of Peritoneal Metastases. Ann Surg Oncol, 25(8), 2165-2171. ()
    33. Lambert LA, Hendrix RJ (2018). Palliative Management of Advanced Peritoneal Carcinomatosis. Surg Oncol Clin N Am, 27(3), 585-602. ()

    Conference Proceedings

    1. Hbner M, Kusamura S, Villeneuve L, Al-Niaimi A, Alyami M, Balonov K, Bell J, Bristow R, Guiral DC, Fagotti A, Falco LFR, Glehen O, Lambert L, Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar SP, Wadhwa A, Altman A, Fawcett W, Veerapong J, Nelson G (2020). Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management. Eur J Surg Oncol, England, 46(12), 2292-2310. ()

    Letter

    1. Lambert LA (2017). Medical Assistance in Dying. [Letter to the editor]. N Engl J Med, 377(9), 897. ()

  • News & Podcasts

    Huntsman Cancer Institute News